Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Regeneron Pharmaceuticals
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows:

- sales of products (65.5%);

- supply of collaborative services (27.9%): working with Sanofi (50% of sales) and Bayer (50%);

- sales of technology licenses (6.6%). The group also provides subcontracting research services.

At the end of 2020, the group had a portfolio of 32 products in clinical development.

Number of employees : 9 123 people.
Sales per Business
20192020Delta
Medicines7 863.40100%8 497.10100% +8.06%
USD in Million
Sales per region
2020
United States5 567.6065.5%
Rest of World2 372.5027.9%
Other557.006.6%
USD in Million
Managers
Name Title Age Since
Leonard Schleifer Chairman, Co-President & CEO 68 1990
George Yancopoulos Co-President, Director & Chief Scientific Officer 61 2001
Robert Landry Chief Financial Officer & Executive VP-Finance 57 2019
Neil Stahl SVP-Preclinical Development 64 2000
Andrew Murphy Executive Vice President-Research 63 2019
Bob McCowan Chief Information Officer & Senior VP-IT - -
Patrice Gilooly Senior VP-Quality Assurance & Operations - 1998
Beth Levine Chief Compliance Officer & Senior Vice President 57 2008
Michael S. Brown, Dr. Independent Director 80 1991
Joseph L. Goldstein, Dr. Independent Director 80 1991
Members of the board
Name Title Age Since
P. Vagelos Chairman 92 1995
Leonard Schleifer Chairman, Co-President & CEO 68 1990
Michael S. Brown, Dr. Independent Director 80 1991
Joseph L. Goldstein, Dr. Independent Director 80 1991
George L. Sing Independent Director 71 1988
George Yancopoulos Co-President, Director & Chief Scientific Officer 61 2001
Arthur Frederick Ryan Independent Director 78 2003
Christine A. Poon Independent Director 68 2010
Marc Tessier-Lavigne Independent Director 61 2011
Bonnie L. Bassler, Dr. Independent Director 59 2016
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 123,650,125 102,565,354 82.9% 17,930,390 14.5% 81.7%
Stock B 10 1,823,283 0 0.0% 0 0.0%
Shareholders
NameEquities%
Fidelity Management & Research Co. LLC 8,938,846 8.46%
The Vanguard Group, Inc. 7,638,297 7.23%
Capital Research & Management Co. (World Investors) 5,320,000 5.03%
SSgA Funds Management, Inc. 4,640,005 4.39%
Wellington Management Co. LLP 3,368,065 3.19%
JPMorgan Investment Management, Inc. 3,104,789 2.94%
Loomis, Sayles & Co. LP 2,756,735 2.61%
Capital Research & Management Co. (Global Investors) 2,754,098 2.61%
BlackRock Fund Advisors 2,452,070 2.32%
Icahn Associates Holding LLC 2,444,081 2.31%
Holdings
NameEquities%Valuation
INTELLIA THERAPEUTICS, INC. (NTLA) 3,702,995 4.98% 437,842,129 USD
DECIBEL THERAPEUTICS, INC. (DBTX) 2,097,314 8.42% 9,752,510 USD
Markets and indexes
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 500, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  REGN.O
- Datastream Code :  
Company contact information
Regeneron Pharmaceuticals
777 Road Old Saw Mill River
NY 10591 Tarrytown, New York

Phone : +1 (914) 847 7000
Fax :
web site : http://www.regeneron.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Regeneron Pharmaceuticals
Sector Bio Therapeutic Drugs